Literature DB >> 12619042

Dopamine transporter gene, response to methylphenidate and cerebral blood flow in attention-deficit/hyperactivity disorder: a pilot study.

Luis A Rohde1, Tatiana Roman, Claudia Szobot, Renato D Cunha, Mara H Hutz, Joseph Biederman.   

Abstract

The homozygosity of the 10-repeat allele at dopamine transporter gene (DAT1) seems to be associated with a poor response to methylphenidate (MPH) in children with attention-deficit/hyperactivity disorder (ADHD). This pilot study aimed to simultaneously assess polymorphisms at DAT1, response to MPH, and neuroimaging. Only ADHD children with at least a moderate response to MPH were included. Significantly higher regional cerebral blood flows assessed by single photon emission computerized tomography (SPECT) were detected in medial frontal and left basal ganglia areas in children with homozygosity for the 10-repeat allele at DAT1 gene (n = 4) than in children without this genotype (n = 4) (P < 0.05). These findings provide a preliminary connection between pharmacogenetics and neurobiological investigations on stimulant treatment of ADHD. Copyright 2003 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12619042     DOI: 10.1002/syn.10186

Source DB:  PubMed          Journal:  Synapse        ISSN: 0887-4476            Impact factor:   2.562


  12 in total

Review 1.  Genetic factors modulating the response to stimulant drugs in humans.

Authors:  Amy B Hart; Harriet de Wit; Abraham A Palmer
Journal:  Curr Top Behav Neurosci       Date:  2012

2.  The influence of genetic variants on striatal dopamine transporter and D2 receptor binding after TBI.

Authors:  Amy K Wagner; Joelle M Scanlon; Carl R Becker; Anne C Ritter; Christian Niyonkuru; Clifton E Dixon; Yvette P Conley; Julie C Price
Journal:  J Cereb Blood Flow Metab       Date:  2014-05-21       Impact factor: 6.200

3.  Attention deficit and hyperactivity disorder among school children in Kinshasa, Democratic Republic of Congo.

Authors:  E Kashala; T Tylleskar; I Elgen; K T Kayembe; K Sommerfelt
Journal:  Afr Health Sci       Date:  2005-09       Impact factor: 0.927

Review 4.  Neuroimaging in psychiatric pharmacogenetics research: the promise and pitfalls.

Authors:  Mary Falcone; Ryan M Smith; Meghan J Chenoweth; Abesh Kumar Bhattacharjee; John R Kelsoe; Rachel F Tyndale; Caryn Lerman
Journal:  Neuropsychopharmacology       Date:  2013-06-24       Impact factor: 7.853

5.  Neurobehavioural deficits associated with apoptotic neurodegeneration and vulnerability for ADHD.

Authors:  Anders Fredriksson; Trevor Archer
Journal:  Neurotox Res       Date:  2004       Impact factor: 3.911

Review 6.  Chronic stress, drug use, and vulnerability to addiction.

Authors:  Rajita Sinha
Journal:  Ann N Y Acad Sci       Date:  2008-10       Impact factor: 5.691

Review 7.  Genetic polymorphisms in the expression and treatment of neuropsychiatric disorders.

Authors:  Thomas W McAllister; Lanier Summerall
Journal:  Curr Psychiatry Rep       Date:  2003-10       Impact factor: 5.285

8.  More aroused, less fatigued: fatty acid amide hydrolase gene polymorphisms influence acute response to amphetamine.

Authors:  Andrea M Dlugos; Ajna Hamidovic; Colin A Hodgkinson; David Goldman; Abraham A Palmer; Harriet de Wit
Journal:  Neuropsychopharmacology       Date:  2009-11-04       Impact factor: 7.853

Review 9.  Attention-deficit hyperactivity disorder in girls: epidemiology and management.

Authors:  Jud Staller; Stephen V Faraone
Journal:  CNS Drugs       Date:  2006       Impact factor: 5.749

Review 10.  Recent advances in the genetics of attention deficit hyperactivity disorder.

Authors:  Lindsey Kent
Journal:  Curr Psychiatry Rep       Date:  2004-04       Impact factor: 5.285

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.